<DOC>
	<DOCNO>NCT02946047</DOCNO>
	<brief_summary>The goal study determine safety tolerability Ixazomib HIV infect patient stable regimen ART suppress HIV replication . A secondary goal determine effect ixazomib size HIV reservoir .</brief_summary>
	<brief_title>The Effect Ixazomib Latent HIV Reservoir</brief_title>
	<detailed_description />
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>The following laboratory value obtain &lt; =14 day prior registration . ANC ≥ LLN ( low limit normal ) ≤ULN ( upper limit normal ) , Hgb ≥ LLN ≤ULN , PLT ≥ LLN ≤ULN Total bilirubin ≤ULN direct bilirubin must ≤ ULN ; AST &lt; 1.5 x ULN ALT &lt; 1.5 x ULN Creatinine &lt; 2.0 x ULN estimate creatinine clearance &gt; 60 ml/min HIV infection suppress viral replication least 3 active drug ART least 6 month Suppressed viral replication define plasma HIV viral load &lt; 20copies/mL . Patient must HIV viral load &lt; 20 copies/ml two occasion least 3 month apart . In opinion treat physician , patient must available regimen likely suppress HIV current regimen fail . Male female patient age &gt; =18 year A plasma HIV RNA viral load demonstrate measure &lt; 20 copies/mL within 30 day prior study initiation . CD4 count &gt; 500 cells/mm3 within 30 day prior study enrollment Females must negative pregnancy test prior receive 1st dose ixazomib postmenopausal least 1 year screen visit , surgically sterile , Male patient , even surgically sterilize ( ie , status postvasectomy ) , must agree one following : Agree practice effective barrier contraception AND second method contraception female partner childbearing potential entire study treatment period 90 day last dose ixazomib , OR Agree practice true abstinence line prefer usual lifestyle subject . ( Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) AND Agree forego sperm donation period . The following laboratory value obtain &lt; =14 day prior registration . ANC &lt; LLN &gt; ULN , Hgb &lt; LLN &gt; ULN , PLT &lt; LLN &gt; ULN Total bilirubin &gt; ULN direct bilirubin &gt; ULN ; AST &gt; 1.5 x ULN AST &gt; 1.5 x ULN Creatinine &gt; =2.0 x ULN estimate creatinine clearance &lt; =60mL/min Diagnosed treated malignancy within 5 year randomization , previously diagnose malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection Any infection except HIV ( exclude benign condition unlikely affect modulated treatment ixazomib , e.g . stye furuncle ) , treatment antiinfective agent within 14 day enrollment . Pregnant woman Women childbearing potential Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse , take drug 90 day stop ixazomib . Any history peripheral neuropathy , peripheral neuropathy detect screening period . Major surgery within 14 day study registration Systemic treatment strong CYP3A inducer ( rifampin , rifapentine , rifabutin , carbamazepine , phenytoin , phenobarbital ) , use St. John 's wort . Evidence current uncontrolled cardiovascular condition , include serious cardiac arrhythmia , congestive heart failure , angina , myocardial infarction within past 6 month . QTc &gt; 450 millisecond ( msec ) men &gt; 470 millisecond woman ( 83 ) 12 lead ECG obtain Screening period . Known hepatitis B DNA positive status and/or HBsAg positive and/or HBeAg positive , active hepatitis C replication ( HCV RNA positive ) currently hepatitis C treatment . Known history cirrhosis active liver inflammation , include `` fatty liver '' nonalcohol steatohepatitis ( NASH ) . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Known allergy study medication , analogue excipients various formulation . Any recent concurrent medical condition , Investigator 's opinion , would impose risk patient Known GI disease GI procedure could interfere oral absorption tolerance ixazomib include difficulty swallowing . Participation clinical trial , include investigational agent include trial , within 30 day start trial throughout duration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>ART</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>Therapy</keyword>
	<keyword>Resevoir</keyword>
	<keyword>Cure</keyword>
</DOC>